U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07738497) titled 'Biomarkers and Pharmacogenomics for Precision Depression Therapy' on June 28.
Brief Summary: Background: The clinical management of major depressive disorder (MDD) is hampered by the lack of objective biomarkers and high inter-individual variability in drug response, with conventional antidepressants achieving only a 50% response rate.
Objective and Design: This prospective, randomized, parallel-controlled trial aims to enroll 220 MDD patients, who will be allocated 1:1 to either a pharmacogenomics (PGx)-guided therapy group (treatment selection based on genetic testing) or a conventional treatment group (treatment as usual per guid...